Tris

ANGUS To Expand U.S. Manufacturing Capacity For TRIS AMINO™ Tromethamine Buffers

Thursday, October 14, 2021 - 2:00pm

BUFFALO GROVE, Ill., Oct. 14, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications, today announced plans to expand U.S. production capacity for its complete portfolio of TRIS AMINO tromethamine buffers.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 14, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications, today announced plans to expand U.S. production capacity for its complete portfolio of TRIS AMINO tromethamine buffers.
  • The planned expansion includes the addition of a fourth dedicated manufacturing line at ANGUS' existing facility in Sterlington, Louisiana, and will roughly double the Company's global TRIS AMINO buffer production capacity.
  • Today, the company produces high-purity, multi-compendial grades of TRIS AMINO products for the life sciences and personal care markets at its Sterlington and recently expanded Ibbenbren, Germany manufacturing facilities.
  • Between 2016 and 2021, ANGUS doubled TRIS AMINO production capacity.

ANGUS Appoints Biopharma Executive Julie O'Neill To Board Of Directors

Wednesday, October 6, 2021 - 2:00pm

BUFFALO GROVE, Ill., Oct. 6, 2021 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients for biotechnology, pharmaceutical, consumer and industrial applications, today announced the appointment of Julie O'Neill to the Company's Board of Directors.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 6, 2021 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients for biotechnology, pharmaceutical, consumer and industrial applications, today announced the appointment of Julie O'Neill to the Company's Board of Directors.
  • O'Neill is a results-driven biopharmaceutical executive, with more than two decades of leadership experience and currently serves on the board of several leading life sciences companies.
  • "We are thrilled to welcome Julie to our board.
  • "I am delighted to join the Board of Directors of ANGUS," said O'Neill.

Neumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021

Monday, September 20, 2021 - 1:00pm

MORRISTOWN, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an award this year for Most Successful Early-Phase Research Company. Neumentum is pioneering the development of a powerful, effective nonopioid analgesic agent for use to control postoperative pain. This early-phase research study was designed to test the safety and toxicology of a 48-hour continuous infusion regimen of ketorolac tromethamine (NTM-001) which is intended to provide stable plasma levels of ketorolac rather than the peaks and troughs of bolus dosing. This 48-hour continuous infusion regimen is groundbreaking, and the study successfully demonstrated its safety and toxicology.

Key Points: 
  • MORRISTOWN, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an award this year for Most Successful Early-Phase Research Company.
  • Neumentum is developing a novel continuous infusion of ketorolac tromethamine, NTM-001, to address these limitations associated with the bolus regimen.
  • Citeline Awards are given every year to honor large and small clinical research organizations for outstanding work.
  • NEMA Research is a clinical research organization headquartered in Naples, Florida.

Kimberly-Clark Announces Executive Leadership Changes

Thursday, August 26, 2021 - 1:30pm

DALLAS, Aug. 26, 2021 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE:KMB) today announced a series of executive leadership changes in support of its global business.

Key Points: 
  • DALLAS, Aug. 26, 2021 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE:KMB) today announced a series of executive leadership changes in support of its global business.
  • Wilkinson will continue to report to Chairman and CEO Mike Hsu and will be based in Singapore.
  • "At the same time, I greatly appreciate Aaron's service to Kimberly-Clark including his leadership of our Kimberly-Clark Professional and Asia Pacific consumer businesses and his passion for building brands."
  • To keep up with the latest news and to learn more about the company's nearly 150-year history of innovation, visit kimberly-clark.com .

Nephron Announces FDA Approval of Ketorolac, Signaling New Phase of Growth

Tuesday, December 22, 2020 - 2:42pm

The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials.

Key Points: 
  • The company today announced Food and Drug Administration (FDA) approval of the Nephron Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 60 mg/2 mL (30 mg/mL) in Single-Dose Vials.
  • Ketorolac Tromethamine becomes one of the first ANDA-approved non-respiratory generic medications produced by Nephron, signaling a new phase of company growth.
  • Nephron secured FDA approval for Sodium Chloride IV Bags earlier this year.
  • "We are extraordinarily excited to expand our generic medication portfolio to include non-respiratory products," said Nephron CEO Lou Kennedy.

ANGUS Chemical Company Launches New TRIS AMINO™ AC (ADVANCED CRYSTAL) Buffer Portfolio For Improved Handling And Preparation Of Buffer Solutions

Thursday, July 2, 2020 - 2:00pm

BUFFALO GROVE, Ill., July 2, 2020 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), the world's largest and only fully integrated original manufacturer of TRIS buffers, today announced the full commercial launch of the Company's new TRIS AMINO AC (ADVANCED CRYSTAL) buffer portfolio .

Key Points: 
  • BUFFALO GROVE, Ill., July 2, 2020 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), the world's largest and only fully integrated original manufacturer of TRIS buffers, today announced the full commercial launch of the Company's new TRIS AMINO AC (ADVANCED CRYSTAL) buffer portfolio .
  • TRIS AMINO AC buffers are manufactured at the Company's newly expanded cGMP production facility in Ibbenbren, Germany, providing the market with a dual manufacturing source for ANGUS' industrial, personal care and multicompendial-grade TRIS AMINO tromethamine buffers.
  • "ANGUS continues to invest in capacity expansion to meet the surging global demand for TRIS AMINO buffers in both highly regulated and industrial applications," said Laura Kaepplinger, Global Segment Leader for ANGUS Life Sciences.
  • "With a larger, more rounded particle structure, TRIS AMINO AC buffers are less prone to clumping and hardness even when subjected to the more aggressive handling and storage conditions."

ANGUS Chemical Company Launches New TRIS AMINO™ AC (ADVANCED CRYSTAL) Buffer Portfolio For Improved Handling And Preparation Of Buffer Solutions

Thursday, July 2, 2020 - 2:00pm

TRIS AMINO AC buffers are manufactured at the Company's newly expanded cGMP production facility in Ibbenbren, Germany, providing the market with a dual manufacturing source for ANGUS' industrial, personal care and multicompendial-grade TRIS AMINO tromethamine buffers.

Key Points: 
  • TRIS AMINO AC buffers are manufactured at the Company's newly expanded cGMP production facility in Ibbenbren, Germany, providing the market with a dual manufacturing source for ANGUS' industrial, personal care and multicompendial-grade TRIS AMINO tromethamine buffers.
  • "ANGUS continues to invest in capacity expansion to meet the surging global demand for TRIS AMINO buffers in both highly regulated and industrial applications," said Laura Kaepplinger, Global Segment Leader for ANGUS Life Sciences.
  • "We leveraged decades of ANGUS TRIS manufacturing expertise to develop the proprietary process and technology used to produce the unique crystal morphology of our new TRIS AMINO AC buffers," said Dr. Dave Green, Vice President, ANGUS Research and Development.
  • "With a larger, more rounded particle structure, TRIS AMINO AC buffers are less prone to clumping and hardness even when subjected to the more aggressive handling and storage conditions."

Tris Pharma Launches New Corporate Website

Thursday, June 25, 2020 - 12:30pm

Tris' previous website was launched when the company had only a single branded commercial product.

Key Points: 
  • Tris' previous website was launched when the company had only a single branded commercial product.
  • Since that time, Tris has expanded its branded portfolio to include two additional ADHD products, significantly extending Tris' leadership position in the pediatric ADHD space.
  • Among other goals, Tris expects its new corporate website to be a tool to explore a range of value-adding partnerships , as well as recruit talented individuals .
  • More information about Tris' technology as well as the Tris Pharma family of ADHD medications can be found by visiting TrisADHD.com .

Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter in Reserve Samples

Monday, April 20, 2020 - 5:30pm

Particulate matter was found in eight reserve sample vials.

Key Points: 
  • Particulate matter was found in eight reserve sample vials.
  • View the full release here: https://www.businesswire.com/news/home/20200420005634/en/
    Fresenius Kabi USA, LLC is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.
  • Ketorolac Tromethamine, a nonsteroidal anti-inflammatory drug, is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
  • The total combined duration of use of oral Ketorolac Tromethamine and Ketorolac Tromethamine injection should not exceed 5 days.

ANGUS Chemical Company Announces Commercial Availability Of TRIS AMINO™ Tromethamine Crystals From Newly Expanded Manufacturing Facility In Germany

Wednesday, November 20, 2019 - 8:00am

BUFFALO GROVE, Ill., Nov. 20, 2019 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty and fine chemicals, today announced the availability of the first commercial volumes of TRIS AMINO tromethamine crystals from the Company's newly expanded manufacturing facility in Ibbenbren, Germany.

Key Points: 
  • BUFFALO GROVE, Ill., Nov. 20, 2019 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty and fine chemicals, today announced the availability of the first commercial volumes of TRIS AMINO tromethamine crystals from the Company's newly expanded manufacturing facility in Ibbenbren, Germany.
  • The addition of new TRIS AMINO production capacity at the Company's existing Ibbenbren site provides the market with a second ANGUS manufacturing source for TRIS AMINO crystals, further enhancing supply chain continuity and security for its customers.
  • "This most recent capacity expansion builds on ANGUS' decades-long commitment to underwrite fast-growing global demand for TRIS AMINO tromethamine.
  • The company innovates through its unique nitroalkane chemistries, which are produced at fully integrated, ISO 9001-certified manufacturing facilities in Sterlington, Louisiana, USA, and Ibbenbren, Germany.